For how we live.
In 544 pregnant women followed across Rio de Janeiro state, adverse maternal outcomes hit 18% of confirmed Oropouche infections versus 7% without, with fetal loss and haemorrhage risks roughly tripled.
A nationwide Brazilian cohort of 4.1 million children found that babies exposed to Zika in the womb but without congenital Zika syndrome had the same pneumonia-hospitalisation risk as unexposed children.
A Manaus trial found chloroquine alone let 27% of Plasmodium vivax patients relapse by day 42; dihydroartemisinin-piperaquine cut that to 2.4%. Paired with primaquine, both drugs did well.
Across 166,390 tests during Brazil's outbreak, two TAK-003 doses were 73% effective against symptomatic dengue and 88% against hospitalisation, with no sign of waning.
Tungiasis, on WHO's neglected-disease list since 2021 but never quantified, costs up to 379,645 healthy life-years a year — rising to 575,298 once its complications are counted.
More than 410,000 probable cases so far in 2026, against 1.45 million for all of 2025. One state, Minas Gerais, accounts for roughly a sixth of the national case total on its own.
A national analysis of 2,985 haemorrhage deaths from 2015 to 2024 found no significant change over time — and Indigenous women dying at 2.87 times the rate of White women.
A Brazilian laboratory study found both a prototype strain and an emergent reassortant killed neural progenitors and collapsed cortical structure. This is a dish, not a pregnancy.
A blinded comparison of 180 responses from a university telehealth centre in Minas Gerais found AI matched human specialists on medical adequacy and risk, and beat them on comprehensibility.
An analysis of 15 years of case data from Altamira, in the Xingu Basin, finds forest edge and local population size — not climate — explained where transmission returned.
Fine particulate exposure in seven Amazonian capitals was tied to about 5,472 circulatory and 2,621 respiratory deaths over six years. A separate analysis finds cardiac mortality rising with forest loss.
A comparison of FDA, EMA and ANVISA decisions from 2020 to 2024 finds Brazilian approvals arriving about a year later. A second study clocks the wait for public-system financing in years, not months.
Anvisa's five new resolutions build a controlled supply chain from seed to shelf, including a regulatory sandbox for patient associations. Analysts say the framework's biggest gap is the one it did not close.
Shared cell time raises transmission odds sharply — six months of it doubles them. But cell-level exposure explains only part of the genomic clustering, which undercuts contact tracing as a strategy.
A WHO and Brazil special report released on the summit's Health Day says extreme heat kills over 540,000 people a year and that health facilities face 41% higher weather-damage risk than in 1990.
The causes recorded do not look like a textbook heat event: nonspecific findings, nervous system disease and mental disorders led the excess, and deaths at home rose 64%.